One US lot of Breckenridge propranolol hydrochloride extended-release capsules, 60 mg, has been recalled because of possible metal contamination. The notice concerns a specific product and batch, not every propranolol prescription. People who may have the affected supply need to check it with their pharmacy and get prompt advice about a replacement.
The company announced the recall on 16 November 2026; the US Food and Drug Administration published the announcement on 20 November. Breckenridge said it had not received reports of adverse events assessed as related to the recall at the time of its announcement. That does not establish that nobody has been affected since, or that the recalled supply is safe to use.
Which propranolol product is affected?
The recall identifies the following combination of details:
- Product: propranolol hydrochloride extended-release capsules, USP, 60 mg.
- Company: Breckenridge Pharmaceutical, Inc.; manufactured by Adare Pharma Solutions.
- Pack: a 100-capsule bottle.
- NDC product code: 51991-817-01.
- Lot number: PK25110035.
- Expiry: May 2029.
The affected lot was supplied to US wholesalers and pharmacies between 26 October and 4 November 2026. Those are distribution dates, not a rule that a patient must have collected their prescription during that period to be affected. A pharmacy may have dispensed stock later.
The medicine name or 60 mg strength alone is not enough to identify the recalled batch. If your pharmacy supplied capsules in a different container, the manufacturer’s lot number may not appear on your patient label. Ask the dispensing pharmacy to check its records and the stock used for your prescription. Do not try to identify a batch from capsule colour or an online photograph alone.
Why has this lot been recalled?
According to the FDA-hosted company announcement, the affected lot shared intermediate material suspected to be linked to metal contamination found in a separate lot that was not released for sale. This is a precaution about potential contamination; it is not confirmation that every capsule in the recalled lot contains metal.
The stated concern is injury to soft tissue in the mouth or digestive tract, including the food pipe, stomach or intestine. Breckenridge is recalling the product down to consumer level, meaning the action includes medicine already supplied to patients rather than only stock still at wholesalers.
What should someone with the affected lot do?
The recall announcement instructs people with the named lot to stop taking that affected product and contact their doctor or healthcare provider for medical advice and replacement instructions. It also asks them to return unused affected medicine to the pharmacy that supplied it. Contact the pharmacy and treating team promptly so that the product issue and ongoing treatment can be addressed together.
This lot-specific recall instruction should not be confused with a general instruction for everyone taking propranolol to stop treatment. The official propranolol extended-release prescribing information warns that abrupt withdrawal can worsen angina and has been associated with heart attacks. Do not make up a taper, change the dose, share another person’s medicine or substitute a different formulation yourself. Get individual instructions from the treating professional, including what to do if the next dose is due before a replacement is available.
If the lot is uncertain, ask the pharmacy to resolve it rather than assuming either that your medicine is affected or that it is unaffected. If you have symptoms or problems that may be connected with taking the recalled supply, seek medical assessment; do not wait for a recall enquiry service to assess an urgent problem.
Why mention this on a diabetes website?
Propranolol is a beta-blocker, not a glucose-lowering medicine. Some people with diabetes take it for another condition. Its prescribing information also warns that beta-blockade can make some warning signs of low blood glucose less obvious, particularly changes in heart rate. Propranolol has itself been associated with hypoglycaemia in certain circumstances. These are existing medicine precautions, not effects newly established by this recall.
For background on symptoms that can overlap, see our guide to anxiety and low blood glucose. The recall does not create a new instruction to alter insulin or other diabetes medicines. A pharmacist or prescriber can take both the recalled product and the person’s other treatment into account.
Questions for the pharmacy
- Does the manufacturer’s product code and lot match the recalled supply?
- Can you check the original stock bottle if my patient container has no lot number?
- How can my prescriber and pharmacy arrange an appropriate replacement?
- What instructions should I follow while that is being arranged, and how should I return the affected capsules?
For recall enquiries, the announcement lists Qualanex on 1-855-736-0807, Monday to Friday, 9 am to 5 pm US Eastern Time. Suspected adverse reactions or product-quality problems can also be reported through FDA MedWatch. Reporting does not replace medical care.
Outside the United States: this announcement describes US distribution. It does not establish a recall of every propranolol product in the UK, EU, Saudi Arabia or elsewhere. Check any local notice and ask your pharmacy about the exact product supplied to you.
Sources
- FDA: Breckenridge propranolol extended-release 60 mg recall announcement, published 20 November 2026.
- DailyMed: propranolol hydrochloride extended-release prescribing information, for general medicine warnings, not identification of the recalled batch.
General information only. Your pharmacist or treating professional can advise on your own medicine and circumstances.